* If you want to update the article please login/register
We analyzed the genomic landscape pre- and post-entrectinib treatment, establishing the clinical reliability of F1L CDx as an aid in identifying patients with NTRK/rotor ROS1fp tumors and assessing the genomic landscape pre- and post-ententrectinib treatment. Positive percentage results between F1L CDx and clinical trial assays were 47. 4% and 65. 5 percent in both clinical and experimental samples, according to the positive predictive value, which was 100 percent for both. In both cohorts, the objective response rate for CTA+ F1L CDx+ patients was 72%. In ROS1-fp but not NTRKfp patients, the median duration of response varied significantly between F1L CDx+ and F1L CDx samples.
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions